NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis $1.46 -0.06 (-3.95%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TherapeuticsMD Stock (NASDAQ:TXMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TherapeuticsMD alerts:Sign Up Key Stats Today's Range$1.46▼$1.5450-Day Range$0.73▼$1.5252-Week Range$0.70▼$2.44Volume23,142 shsAverage Volume155,286 shsMarket Capitalization$16.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More… TherapeuticsMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreTXMD MarketRank™: TherapeuticsMD scored higher than 28% of companies evaluated by MarketBeat, and ranked 776th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for TherapeuticsMD. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.29% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently decreased by 13.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.29% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently decreased by 13.42%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.14 News SentimentTherapeuticsMD has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.Search Interest3 people have searched for TXMD on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,803.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of TherapeuticsMD is held by insiders.Percentage Held by InstitutionsOnly 30.74% of the stock of TherapeuticsMD is held by institutions.Read more about TherapeuticsMD's insider trading history. Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Stock News HeadlinesTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13 at 4:05 PM | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12 at 10:12 PM | marketwatch.comSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. Industrial demand is rising fast, but new supply isn't keeping pace. For investors, that opens the door to one key question: who already has it? One project in N. America just reported high-grade results at a time when ounces in the ground are becoming harder to find-and more valuable.May 14, 2025 | i2i Marketing Group, LLC (Ad)TherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Friday, still outperforms marketDecember 27, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 23, 2024 | marketwatch.comSee More Headlines TXMD Stock Analysis - Frequently Asked Questions How have TXMD shares performed this year? TherapeuticsMD's stock was trading at $0.86 on January 1st, 2025. Since then, TXMD shares have increased by 69.8% and is now trading at $1.46. View the best growth stocks for 2025 here. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) released its earnings results on Tuesday, May, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $0.39 million for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative trailing twelve-month return on equity of 14.08%. When did TherapeuticsMD's stock split? TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are TherapeuticsMD's major shareholders? TherapeuticsMD's top institutional investors include Tejara Capital Ltd (2.98%) and Simplex Trading LLC. Insiders that own company stock include Rubric Capital Management Lp, Marlan D Walker, Cooper C Collins, Michael C Donegan, Brian Bernick and Gail K Naughton. View institutional ownership trends. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Marinus Pharmaceuticals (MRNS), AUO (AUOTY) and The RMR Group (RMR). Company Calendar Last Earnings5/13/2025Today5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees420Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,280,000.00 Net Margins-207.77% Pretax Margin-251.25% Return on Equity-14.08% Return on Assets-9.61% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual Sales$1.76 million Price / Sales9.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book0.54Miscellaneous Outstanding Shares11,574,000Free Float11,267,000Market Cap$17.25 million OptionableOptionable Beta0.50 Social Links 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:TXMD) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Musk’s Next Big BetCancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCan This System Really Predict Stocks to the Day?Imagine foreseeing a 30% stock jump — to the day — weeks before it happens. Introducing a new way to predict t...InvestorPlace | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.